Silverarc Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Silverarc Capital Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,124	Closed	-$2.96M	–	90
2025 Q4	$2.96M	Buy	+36,124	New	+$2.7M	0.41%	53
2025 Q2	–	Sell	-81,331	Closed	-$4.18M	–	83
2025 Q1	$4.18M	Buy	81,331 +15,376	+23%	+$760K	0.85%	29
2024 Q4	$3.65M	Buy	65,955 +25,955	+65%	+$1.18M	0.8%	36
2024 Q3	$1.32M	Hold	40,000	–	–	0.3%	53
2024 Q2	$1.09M	Buy	+40,000	New	+$1.34M	0.26%	56

Other funds holding TARS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Silverarc Capital Management's TARS Position: Q1 2026 in Review

Silverarc Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 36,124 shares — an estimated $2.96M sold.

Silverarc Capital Management first reported a position in TARS in Q2 2024 and held it in 5 quarters. The position peaked at $4.18M in Q1 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

Silverarc Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Silverarc Capital Management sold 36,124 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $2.96M.
Silverarc Capital Management first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 5 quarters.
Silverarc Capital Management's Tarsus Pharmaceuticals position peaked at $4.18M in Q1 2025.
253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.